← Back to all trials
Completed
NCT05018299
Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
Conditions: Severe Asthma
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 21
Sponsor: Oneness Biotech Co., Ltd.
Location: Kaohsiung Chang Gung Memorial Hospital Kaohsiung City
Summary
This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.
Eligibility Criteria
Inclusion Criteria:
1.18 to ≦75 years of age, either sex, any race.
2.Diagnosed as severe asthma based on 2020 GINA guideline.
3.An ACT score is \
Source: ClinicalTrials.gov (NCT05018299). StuddyBuddy aggregates publicly available trial information.
